EmbectavsMerck & Company

EMBC and MRK stock compared: price, dividend, valuation and results, from SEC filings.

EMBC

Embecta Corp.

$6.19

Value $362M

+1.64%
EMBC's page

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

Embecta (EMBC) has a market value of $362M and Merck & Company (MRK) $328B. Over the last year, with dividends, EMBC moved -55.0% and MRK +41.8%. The P/E is 4.1 for EMBC and 133.9 for MRK. Dividend yield: EMBC 5.17%, MRK 2.56%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EMBC$362M

    MRK$328B

    MRK is 907 times EMBC

  • Revenue, 12 months

    EMBC$1.0B

    MRK$67.4B

    MRK is 66 times EMBC

  • Net income, 12 months

    EMBC$88M

    MRK$2.5B

    MRK is 28 times EMBC

  • Operating margin

    EMBC21.9%

    MRK–

  • ROIC

    EMBC20.4%

    MRK3.9%

    16.5 points apart

  • P/E

    EMBC4.1

    MRK133.9

    MRK is 32 times EMBC

  • Dividend yield

    EMBC5.2%

    MRK2.6%

    2.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EMBC-58.2%

MRK+43.1%

50100150202420252026
Returns by period
PeriodEMBCWith dividendsMRKWith dividends
1 year since November 18, 2025-55.0%Price -56.4%+41.8%Price +37.7%
3 years since November 17, 2023-58.2%-25.2% a yearPrice -62.8%+43.1%+12.7% a yearPrice +30.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EMBCEmbectaMRKMerck & Company

Valuation

EMBCMRK
Valuation
Price$6.19$132.81
Market value$362M$328B
Enterprise value (EV)$1.6B$372B
P/E4.1133.9
P/E, 5-year median9.614.8
P/B–7.3
EV/EBIT7.378.2
Free cash flow yield45.5%4.5%

Results and growth

EMBCMRK
Results and growth
Revenue, 12 months$1.0B$67.4B
Net income, 12 months$88M$2.5B
Free cash flow, 12 months$165M$14.7B
Earnings per share, 12 months$1.47$0.98
Revenue growth, year on year-3.8%1.3%
Revenue growth a year, past-0.1%over 5 years+9.4%over 5 years
EPS growth a year, past-26.4%over 5 years+21.2%over 5 years

Margins and returns on capital

EMBCMRK
Margins and returns on capital
Gross margin59.0%71.8%
Operating margin21.9%–
Net margin8.6%3.6%
ROIC20.4%3.9%
ROE–5.2%

Balance sheet

EMBCMRK
Balance sheet
Cash$215M$9.7B
Total debt$1.5B$53.8B
Net debt / EBITDA4.85.7
Interest cover–2.4×

Dividends and buybacks

EMBCMRK
Dividends and buybacks
Dividend yield5.2%2.6%
Dividend per share, 12 months$0.32$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.6%
Shareholder yield5.2%4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EMBC or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Embecta or Merck & Company?

By market value, Merck & Company ($328B) is about 906.6 times Embecta ($362M), at today's prices.

How did EMBC and MRK stock do over the last 3 years?

Since November 17, 2023, EMBC's price moved -62.8% and MRK's +30.5%. With dividends: EMBC -58.2% (-25.2% a year), MRK +43.1% (+12.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, EMBC or MRK?

The dividend yield at today's price is 5.17% for Embecta and 2.56% for Merck & Company. Over the last twelve months they paid $0.32 and $3.40 per share.

What is the P/E of EMBC and MRK?

At today's price, the P/E is 4.1 for EMBC and 133.9 for MRK. The median of the last five years was 9.6 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Embecta or Merck & Company?

Over the last twelve months, the net margin was 8.6% for Embecta and 3.6% for Merck & Company, and the operating margin 21.9% and –. Revenue was $1.0B and $67.4B.

Which is the better investment, Embecta or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.